Efficient generation of transgenic BALB/c mice using BALB/c embryonic stem cells

被引:24
作者
Dinkel, A
Aicher, WK
Warnatz, K
Bürki, K
Eibel, H
Ledermann, B [1 ]
机构
[1] Novartis Pharma, Preclin Res, CH-4002 Basel, Switzerland
[2] Univ Freiburg, Med Ctr, Clin Res Unit Rheumatol, D-79106 Freiburg, Germany
[3] Univ Freiburg, Dept Biol, D-79108 Freiburg, Germany
关键词
BALB/c; transgenic; embryonic stem cells; Egr-1; B cells;
D O I
10.1016/S0022-1759(99)00005-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
BALB/c is one of the most widely used and best characterized mouse strains in immunology. For various applications, it is necessary to generate BALB/c transgenic mice. However, using the conventional microinjection technique it is extremely inefficient to produce transgenic BALB/c mice since the one-cell stage BALB/c embryos are highly vulnerable to pronuclear DNA microinjection. To overcome this problem, we have investigated the generation of Egr-1 (early growth response gene) transgenic mice via the transfection of BALB/c embryonic stem cells. Transfectants carrying Egr-1 constructs comprising either the immunoglobulin heavy chain or the MHC class II promoter/enhancer system were injected into C57BL/6 host blastocysts resulting in chimeric mice. For both type of expression vectors, transgenic offspring of the germline chimeras expressed recombinant Egr-1 in lymphoid tissues containing B cells. This demonstrates the successful generation of Egr-1 transgenic BALB/c mice using transfected ES cell. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 14 条
[11]   DIFFERENTIAL EXPRESSION OF A ZINC FINGER-ENCODING GENE IN RESPONSE TO POSITIVE VERSUS NEGATIVE SIGNALING THROUGH RECEPTOR IMMUNOGLOBULIN IN MURINE LYMPHOCYTES-B [J].
SEYFERT, VL ;
SUKHATME, VP ;
MONROE, JG .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (05) :2083-2088
[12]   Induction of the early growth response (Egr) family of transcription factors during thymic selection [J].
Shao, H ;
Kono, DH ;
Chen, LY ;
Rubin, EM ;
Kaye, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :731-744
[13]  
TAKEUCHI T, 1993, J INVEST DERMATOL, V100, P141
[14]  
ZIPFEL PF, 1989, J IMMUNOL, V142, P1582